On July 31, HRSA announced a revised 340B Rebate Model Pilot Program set to take effect January 1, 2027, replacing upfront 340B discounts with post-dispense rebates for certain high-cost drugs. While manufacturer participation is voluntary, covered entities have no opt-out, meaning any entity purchasing an affected manufacturer’s drugs must comply.
This white paper breaks down the Pilot’s mechanics, key deadlines, data and reporting requirements, and the operational challenges covered entities should anticipate — from claims-data integration to cash-flow exposure and audit implications. It also examines HRSA’s response to stakeholder comments and identifies gaps in the agency’s cost and cash-flow analysis.
Download the full whitepaper to understand what’s changing, what to do before January 2027, and how Advis can help your organization prepare.
For questions, contact Advis today via our website here or by phone at (708) 478-7030.
Published: August 13, 2026